Our study reveals that combined targeting of ATR and RNR was effective against Ewing’s sarcoma in vitro and thus rationalises an in vivo exploration into the potential of combining ATR and RNR inhibitors as a new strategy for the treatment of this challenging disease. This evidence concerns the gene ATR and Ewing sarcoma.